Table 2.

Secondary treatment for chronic GVHD

Treatment	Study type	No. of patients	% Overall Response	Overall Survival	Reference
Therapies reported during the two years review period
Extracorporeal photopheresis (ECP)	Phase II	23	70	78%	[27]
	Retrospective	43	65	70%/1-yr	[28]
	Retrospective	9	67		[29]
Rituximab	Phase II	37	86	72%/1-yr	[31]
	Meta-analysis	111	66		[33]
Imatinib	Phase I/II	19	79	84%/1.5-yr	[11]
	Phase I/II	9	22	78%/1.5-yr	[12]
	Retrospective	14	50	75%/1.5-yr	[13]
Pentostatin	Phase II	51	53	60%/3-yr	[34]
	Retrospective	18	56	34%/1-yr	[35]
Mesenchymal stem cells infusions (MSC)	Phase I/II	19	74	78%/2-yr	[37]
	Phase I/II	8	50		[38]
Mycophenolate mofetil	Retrospective	23	26a	96%/1-yr	[39]
	Retrospective	11	64	67%/1-yr	[40]
mTOR inhibitor	Retrospective	34	76	72%/3-yr	[42]
Other therapies summarized in recent reviews					[17,25,46]
Calcineurin inhibitor			20 – 82% overall response rates reported
High-dose methylprednisolone
Methotrexate
Thalidomide
Hydroxychloroquine
Clofazimine
Thoracoabdominal irradiation
Alefacept
Infliximab

mTOR, mammalian target of rapamycin.

^aResponse was defined as discontinuation of all immunosuppressive treatment by 3 years.